Antisoma reports prostate cancer data

Antisoma (LSE:ASM) said ASA404 plus docetaxel did not meet the endpoint of median survival vs. docetaxel alone (17 vs. 17.2 months, respectively) in a Phase II trial in 74 patients with metastatic hormone-refractory prostate cancer. The combination did result in two-year survival of 33% vs. 23% for docetaxel alone in the U.S. and Australian study. ...